AR shows context-dependent roles in ER breast cancers that loss of ARID1A disrupts chromatin regulators affecting drug sensitivities and self-regulation of ER; thus, future investigation of ARID1A-AR interactions across breast cancer subtypes is necessary [27,32]. Here, ARID1A is linked to breast cancer.